[go: up one dir, main page]

AR073116A1 - Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes. - Google Patents

Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes.

Info

Publication number
AR073116A1
AR073116A1 ARP090103233A ARP090103233A AR073116A1 AR 073116 A1 AR073116 A1 AR 073116A1 AR P090103233 A ARP090103233 A AR P090103233A AR P090103233 A ARP090103233 A AR P090103233A AR 073116 A1 AR073116 A1 AR 073116A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
group
substituted
membered
Prior art date
Application number
ARP090103233A
Other languages
English (en)
Original Assignee
Novartis Ag
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073116(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Astex Therapeutics Ltd filed Critical Novartis Ag
Publication of AR073116A1 publication Critical patent/AR073116A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptable, en donde: X es CR9 o N; R1 es alquilo C1-8, CN, C(O)OR4 o CONR5R6, un grupo heteroarilo de 5 a 14 miembros, o un grupo ciclo heteroalquilo de 3 a 14 miembros; R2 es alquilo C1-8, cicloalquilo C3-14, o un grupo heteroarilo de 5 a 14 miembros, y en donde R2 puede estar sustituido con uno o más de alquilo C1-8, u OH; L es un enlace, alquileno C1-8, C(O), o C(O)NR10, y en donde L puede estar sustituido o insustituido; Y es H, R11, NR12R13, OH, o Y es parte del grupo de la formula (2) en donde Y es CR9 o N; en donde puede haber de 0 a 3 R8 presentes, y R8 es alquilo C1-8, oxo, halogeno, o dos o más R8 pueden formar un grupo alquilo puenteado; W es CR9 o N; R3 es H, alquilo C1-8, alquilo C1-8-R14, cicloalquilo C3-14, C(O)-alquilo C1-8, halo-alquilo C1-8, alquilo C1-8-OH, C(O)NR14R15, ciano-alquilo C1-8, C(O)R14, alquilo C0-8-C(O)-alquilo C0-8-NR14R15, alquilo C0-8-C(O)OR14, NR14R15, SO2-alquilo C1-8, alquilo C1-8-cicloalquilo C3-14, C(O)-alquilo C1-8-cicloalquilo C3-14, alcoxilo C1-8, u OH, el cual puede estar sustituido o insustituido cuando R3 no es H; R9 es H o halogeno; R4, R5, R6, R7, R10, R11, R12, R13, R14 y R15 se seleccionan cada uno independientemente a partir de H, alquilo C1-8, cicloalquilo C3-14, un grupo ciclo-heteroalquilo de 3 a 14 miembros, un grupo arilo C6-14, un grupo heteroarilo de 5 a 14 miembros, alcoxilo, C(O)H, C(N)OH, C(N)OCH3, C(O)-alquilo C1-3, alquilo C1-8-NH2, alquilo C1-6-OH, y en donde R4, R5, R6, R7, R10, R11, R12, R13, R14, y R15 cuando no son H, pueden estar sustituidos o insustituidos; m y n son independientemente de 0 a 2; y en donde L, R3, R4, R5, R6, R7, R10, R11, R12 y R13, R14 y R15 pueden estar sustituidos con uno o más de alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-14, grupo heteroarilo de 5 a 14 miembros, grupo arilo C6-14, un grupo ciclo-heteroalquilo de 3 a 14 miembros, OH, (O), CN, alcoxilo, halogeno o NH2. Reivindicacion 21: Un compuesto de la formula (3) o una sal farmacéuticamente aceptable del mismo, en donde: R50 es CONR54R55 o CN; R51 es cicloalquilo C3-14 el cual puede estar insustituido o sustituido por alquilo C1-3, u OH; Z es CH o N; y V es NR56 o CHR57; R54 y R55 son independientemente H, o alquilo C1-3; R52, R53, R56 y R57 son independientemente H, alquilo C1-8, cicloalquilo C3-14, halo-alquilo C1-8, NR58R59, C(O)OR60, C(O)-alquilo C1-8, alquilo C0-8-(O)-alquilo C0-8-NR61R62, alcoxilo C1-8, alquilo C1-8-R63, C(O)-grupo ciclo-heteroalquilo de 5 a 14 miembros, grupo cicloalquilo C3-14, cada uno de los cuales, cuando no es H, puede estar sustituido por uno o más de alquilo C1-8, OH o CN; R58, R59, R60, R61, R62 y R63 son H o alquilo C1-8.
ARP090103233A 2008-08-22 2009-08-21 Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes. AR073116A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9103708P 2008-08-22 2008-08-22

Publications (1)

Publication Number Publication Date
AR073116A1 true AR073116A1 (es) 2010-10-13

Family

ID=41171100

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090103233A AR073116A1 (es) 2008-08-22 2009-08-21 Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes.
ARP180101294A AR111763A2 (es) 2008-08-22 2018-05-16 Compuestos de pirrolo-pirimidina y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180101294A AR111763A2 (es) 2008-08-22 2018-05-16 Compuestos de pirrolo-pirimidina y sus usos

Country Status (49)

Country Link
US (8) US8685980B2 (es)
EP (2) EP2331547B1 (es)
JP (2) JP5560496B2 (es)
KR (2) KR20130140222A (es)
CN (2) CN102186856B (es)
AR (2) AR073116A1 (es)
AU (1) AU2009284098B2 (es)
BR (1) BRPI0917791B1 (es)
CA (1) CA2734802C (es)
CL (1) CL2011000306A1 (es)
CO (1) CO6341561A2 (es)
CR (1) CR20110101A (es)
CU (1) CU24062B1 (es)
CY (2) CY1115703T1 (es)
DK (1) DK2331547T3 (es)
DO (1) DOP2011000057A (es)
EA (1) EA019094B1 (es)
EC (1) ECSP11010843A (es)
ES (1) ES2522346T3 (es)
FR (1) FR17C1059I2 (es)
GE (1) GEP20135785B (es)
HK (1) HK1156625A1 (es)
HN (1) HN2011000542A (es)
HR (1) HRP20141018T1 (es)
HU (1) HUS1700051I1 (es)
IL (1) IL211164A (es)
JO (1) JO2924B1 (es)
LT (1) LTC2331547I2 (es)
LU (1) LUC00048I2 (es)
MA (1) MA32555B1 (es)
ME (1) ME01282B (es)
MX (1) MX2011001879A (es)
MY (1) MY150560A (es)
NI (1) NI201100042A (es)
NL (1) NL300909I2 (es)
NO (1) NO2017059I2 (es)
NZ (1) NZ591176A (es)
PE (1) PE20110419A1 (es)
PL (1) PL2331547T3 (es)
PT (1) PT2331547E (es)
RS (1) RS53574B1 (es)
SI (1) SI2331547T1 (es)
SM (1) SMT201500017B (es)
TN (1) TN2011000062A1 (es)
TW (1) TWI468409B (es)
UA (1) UA103628C2 (es)
UY (2) UY38935A (es)
WO (1) WO2010020675A1 (es)
ZA (1) ZA201100994B (es)

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2331547T3 (da) 2008-08-22 2014-11-03 Novartis Ag Pyrrolopyrimidinforbindelser som CDK-inhibitorer
EP2429566B1 (en) 2009-05-13 2016-01-06 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
ES2689177T3 (es) * 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
WO2012024500A1 (en) 2010-08-18 2012-02-23 Life Technologies Corporation Chemical coating of microwell for electrochemical detection device
CN106967074A (zh) * 2010-10-25 2017-07-21 G1治疗公司 Cdk抑制剂
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
AR083797A1 (es) * 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
CN103501789A (zh) 2010-11-17 2014-01-08 北卡罗来纳大学查珀尔希尔分校 通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血
AU2014259534B2 (en) * 2011-01-04 2016-05-19 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
EP2661433B1 (en) * 2011-01-04 2017-08-16 Novartis AG Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
ES2676180T3 (es) 2011-07-01 2018-07-17 Novartis Ag Terapia de combinación que comprende un inhibidor de CDK4/6 y un inhibidor de PI3K para el uso en el tratamiento de cáncer
JP2014522836A (ja) * 2011-07-01 2014-09-08 ノバルティス アーゲー 併用療法
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
US9194840B2 (en) 2012-01-19 2015-11-24 Life Technologies Corporation Sensor arrays and methods for making same
EP2831080B1 (en) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
WO2013163239A1 (en) * 2012-04-26 2013-10-31 Francis Xavier Tavares Synthesis of lactams
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
ES2648962T3 (es) 2012-06-28 2018-01-09 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la vía del complemento
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
US9468661B2 (en) 2012-06-28 2016-10-18 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
KR20150036481A (ko) 2012-07-12 2015-04-07 노파르티스 아게 보체 경로 조절제 및 그의 용도
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
WO2014022830A2 (en) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
WO2014097125A1 (en) 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
EP2959013A2 (en) 2013-02-25 2015-12-30 Novartis AG Novel androgen receptor mutation
CN105189481A (zh) 2013-03-13 2015-12-23 艾伯维公司 吡啶cdk9激酶抑制剂
MX2015012386A (es) * 2013-03-13 2016-02-03 Abbvie Inc Inhibidores de la cinasa cdk9.
EP2970278A4 (en) 2013-03-14 2016-12-07 Abbvie Inc Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
US9346813B2 (en) 2013-03-14 2016-05-24 Abbvie Inc. Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors
WO2014151444A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
US20140274896A1 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
EP2968290B1 (en) 2013-03-15 2019-09-25 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
US20140271460A1 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
MX2015013466A (es) 2013-03-21 2016-06-21 Novartis Ag Terapia de combinacion que comprende un inhibidor deb-raf y un segundo inhibidor.
ES2782003T3 (es) 2013-04-16 2020-09-09 Memorial Sloan Kettering Cancer Center Compañero de diagnóstico para inhibidores de CDK4
ES2900829T3 (es) * 2013-08-14 2022-03-18 Novartis Ag Terapia combinada para el tratamiento del cáncer
US20160361314A1 (en) * 2013-08-28 2016-12-15 Novartis Ag Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
WO2015049325A1 (en) * 2013-10-03 2015-04-09 F. Hoffmann-La Roche Ag Therapeutic inhibitors of cdk8 and uses thereof
WO2015061407A1 (en) * 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
AU2014354821A1 (en) * 2013-11-27 2016-05-26 Novartis Ag Combination therapy comprising an inhibitor of JAK, CDK and PIM
US9476853B2 (en) 2013-12-10 2016-10-25 Life Technologies Corporation System and method for forming microwells
US11013743B2 (en) * 2013-12-20 2021-05-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
CA2931073C (en) * 2013-12-23 2021-10-26 Novartis Ag Pharmaceutical combinations
MX2016008362A (es) * 2013-12-23 2016-09-08 Novartis Ag Combinaciones farmaceuticas.
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
JP6263269B2 (ja) * 2013-12-31 2018-01-17 シュエンジュウ・ファーマ・カンパニー・リミテッド キナーゼ阻害剤及びその使用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CN106659765B (zh) 2014-04-04 2021-08-13 德玛医药 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US20150297607A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
JP2017516855A (ja) * 2014-05-28 2017-06-22 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド 特定のタンパク質キナーゼ阻害剤
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CA3000633C (en) 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
HUE061672T2 (hu) 2014-11-12 2023-08-28 Seagen Inc Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
US10138250B2 (en) 2014-12-12 2018-11-27 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
WO2016091221A1 (zh) * 2014-12-12 2016-06-16 苏州晶云药物科技有限公司 吡咯并[2,3-d]嘧啶化合物的盐及盐的新晶型
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
US10130629B2 (en) 2015-03-25 2018-11-20 Novartis Ag Pharmaceutical combinations
AU2016248017A1 (en) 2015-04-16 2017-10-19 Novartis Ag Ribociclib tablet
CN106146515B (zh) * 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
CA2987019C (en) 2015-05-29 2023-09-26 Teijin Pharma Limited Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
CN105037236B (zh) 2015-06-04 2017-07-28 苏州明锐医药科技有限公司 瑞博西尼中间体及其制备方法
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
US20190365741A1 (en) 2015-08-28 2019-12-05 Novartis Ag Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
CN108348522A (zh) * 2015-08-28 2018-07-31 诺华股份有限公司 含(a)周期素依赖性激酶4/6(cdk4/6)抑制剂lee011(＝ribociclib)和(b)表皮生长因子受体(egfr)抑制剂厄洛替尼的药物组合，用于治疗或预防癌症
JP2018528952A (ja) 2015-08-28 2018-10-04 ノバルティス アーゲー Ｐｉ３ｋ阻害剤のアルペリシブおよびｃｄｋ４／６阻害剤のリボシクリブを含む医薬組合せ、ならびにがんの治療／予防におけるその使用
CN108348513A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 用于治疗或预防癌症的ribociclib与达拉菲尼的组合
EP3156406A1 (en) 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
WO2017083582A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN106749259B (zh) * 2015-11-19 2019-02-01 华东师范大学 一种环戊基嘧啶并吡咯类化合物的合成方法
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
CN105541863B (zh) * 2016-02-16 2017-09-05 安纳康科学股份有限公司 噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
US11921116B2 (en) 2016-03-09 2024-03-05 Memorial Sloan Kettering Cancer Center Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
WO2017162215A1 (zh) * 2016-03-25 2017-09-28 正大天晴药业集团股份有限公司 取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途
CN107266451B (zh) * 2016-04-07 2021-12-31 上海医药工业研究院 瑞布昔利布中间体的制备方法
US10865204B2 (en) 2016-04-22 2020-12-15 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
AU2017262155B2 (en) 2016-05-07 2021-03-11 Fochon Pharmaceuticals, Ltd. Certain protein kinase inhibitors
WO2017211245A1 (zh) * 2016-06-06 2017-12-14 深圳市塔吉瑞生物医药有限公司 一种取代的吡咯并嘧啶化合物及其应用
PL3464272T3 (pl) 2016-06-07 2022-03-28 Jacobio Pharmaceuticals Co., Ltd. Nowe pochodne heterocykliczne użyteczne jako inhibitory SHP2
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
CN109789143A (zh) * 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
AU2017290362B2 (en) 2016-07-01 2021-08-05 G1 Therapeutics, Inc. Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
IL264950B2 (en) 2016-08-23 2024-01-01 Eisai R&D Man Co Ltd Combined treatments for the treatment of malignant liver cell carcinoma
WO2018051280A1 (en) * 2016-09-15 2018-03-22 Dr. Reddy’S Laboratories Limited Process for preparation of ribociclib, its acid addition salts
BR112019005046A2 (pt) 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
EP3528812B1 (en) 2016-10-20 2020-12-30 Pfizer Inc Palbociclib for treating pah
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
WO2018089518A1 (en) 2016-11-08 2018-05-17 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
US11001586B2 (en) 2016-11-17 2021-05-11 The University Of North Carolina At Chapel Hill Alkyl pyrrolopyrimidine analogs and methods of making and using same
IL266313B2 (en) 2016-11-28 2023-12-01 Teijin Pharma Ltd Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
BR112019010674A2 (pt) 2016-11-28 2019-10-01 Teijin Pharma Ltd composto, composição farmacêutica, fármaco para a prevenção ou tratamento de artrite reumatoide, aterosclerose, fibrose pulmonar, infarto cerebral, ou câncer, e, derivado de pirido[3,4-d]pirimidina
IL317919A (en) 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
WO2018140730A1 (en) * 2017-01-27 2018-08-02 Signalrx Pharmaceuticals, Inc. Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
SG11201908531WA (en) 2017-03-16 2019-10-30 Eisai R&D Man Co Ltd Combination therapies for the treatment of breast cancer
NZ758458A (en) 2017-03-23 2022-07-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
KR102641827B1 (ko) 2017-05-02 2024-03-04 노파르티스 아게 병용 요법
CN106946880B (zh) * 2017-05-06 2019-04-26 南京焕然生物科技有限公司 一种制备瑞博西尼中间体的方法
CN107118215B (zh) * 2017-05-06 2019-04-05 上海耀大生物科技有限公司 一种治疗乳腺癌药物瑞博西尼中间体的制备方法
CN107267481A (zh) * 2017-05-09 2017-10-20 上海交通大学医学院附属新华医院 Cdk5抗原表位肽及其应用
CN108929324A (zh) * 2017-05-22 2018-12-04 南开大学 新型1,1-环丙基二酰胺衍生物的制备与应用
CN108929312A (zh) * 2017-05-22 2018-12-04 南开大学 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
TW201906818A (zh) * 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
RU2019142591A (ru) 2017-06-29 2021-07-29 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
MX2020001253A (es) 2017-08-03 2020-07-13 Novartis Ag Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor de quinasa dependiente de ciclina.
EP3672968B1 (en) 2017-08-25 2023-11-01 Assia Chemical Industries Ltd Solid state form of ribociclib succinate
US20230160016A1 (en) 2017-08-31 2023-05-25 Novartis Ag Methods of selecting a treatment for cancer patients
US11286259B2 (en) 2017-09-29 2022-03-29 Hangzhou Solipharma Co., Ltd. Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
KR20200057705A (ko) * 2017-10-27 2020-05-26 프레세니어스 카비 온콜로지 리미티드 리보시클립 및 그의 염의 제조를 위한 개선된 방법
JP2021503448A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー Ｌｓｚ１０２及びリボシクリブを含む医薬組合せ
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
RU2020124138A (ru) 2017-12-22 2022-01-24 Хиберселл, Инк. Производные аминопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
WO2019123364A1 (en) 2017-12-22 2019-06-27 Shilpa Medicare Limited Novel polymorphs of ribociclib mono succinate
US10519136B2 (en) * 2017-12-29 2019-12-31 Accutar Biotechnology Dual inhibitors of PARP1 and CDK
BR112020013915A2 (pt) 2018-01-08 2020-12-01 G1 Therapeutics, Inc. regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano
CN107936029B (zh) * 2018-01-08 2020-06-30 南京奇可药业有限公司 一种合成瑞博西尼的方法
EA202091450A1 (ru) * 2018-01-29 2021-01-14 Бета Фарма, Инк. Производные 2h-индазола в качестве ингибиторов cdk4 и cdk6 и их терапевтические применения
AU2019220746A1 (en) 2018-02-15 2020-08-27 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2019167068A1 (en) 2018-03-01 2019-09-06 Cipla Limited Novel polymorphs of ribociclib succinate
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
US10723739B2 (en) 2018-05-14 2020-07-28 Apotex Inc. Processes for the preparation of Ribociclib and intermediates thereof
WO2019222521A1 (en) * 2018-05-16 2019-11-21 G1 Therapeutics, Inc. Cdk inhibitors for the treatment of neoplastic disorders
CN108558745A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种帕博西林中间体的合成方法
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US12163193B2 (en) 2018-08-13 2024-12-10 Beijing Percans Oncology Co., Ltd. Biomarkers for cancer therapy
EP3840756A4 (en) 2018-08-24 2022-04-27 G1 Therapeutics, Inc. IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE
JP2022500458A (ja) * 2018-09-13 2022-01-04 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. 置換ピロロピリミジン系ｃｄｋ阻害剤の塩とその結晶および使用
WO2020084389A1 (en) 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
AU2019373221B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
UA126619C2 (uk) 2018-10-31 2022-11-02 Гіліад Сайєнсіз, Інк. Заміщені сполуки 6-азабензімідазолу як інгібітори hpk1
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
CN109400612A (zh) * 2018-12-24 2019-03-01 重庆三圣实业股份有限公司 一种瑞博西尼的制备方法及其产品和用途
US20230065740A1 (en) 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220056037A1 (en) * 2018-12-28 2022-02-24 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
JP2022517842A (ja) 2019-01-23 2022-03-10 ノバルティス アーゲー ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態
CN113382731A (zh) 2019-02-12 2021-09-10 诺华股份有限公司 包含tno155和瑞博西尼的药物组合
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020225827A1 (en) 2019-05-08 2020-11-12 Mylan Laboratories Limited Novel polymorphs of ribociclib succinate
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US20220324837A1 (en) * 2019-06-04 2022-10-13 Step Pharma S.A.S. N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
CN118986983A (zh) 2019-08-26 2024-11-22 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
WO2021038590A1 (en) 2019-08-30 2021-03-04 Mylan Laboratories Limited Novel polymorph of ribociclib succinate
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
EP4054583A4 (en) * 2019-11-07 2023-10-25 Crinetics Pharmaceuticals, Inc. MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND THEIR USES
CA3164617A1 (en) * 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
CN116234803A (zh) 2019-12-23 2023-06-06 冰洲石生物科技公司 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
EP4126244A4 (en) * 2020-03-27 2024-03-27 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. COMBINATION OF ANTI-HER2 ANTIBODIES AND CDK INHIBITOR FOR THE TREATMENT OF TUMORS
WO2021227906A1 (zh) * 2020-05-12 2021-11-18 苏州阿尔脉生物科技有限公司 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
EP4149472A1 (en) 2020-05-12 2023-03-22 Novartis AG Therapeutic combinations comprising a craf inhibitor
CN113149996B (zh) * 2020-05-12 2022-12-20 苏州阿尔脉生物科技有限公司 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
WO2021236650A1 (en) 2020-05-19 2021-11-25 G1 Therapeutics, Inc. Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
AU2021388021A1 (en) 2020-11-24 2023-06-22 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
EP4251208A1 (en) 2020-11-24 2023-10-04 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
EP4288434A1 (en) 2021-02-02 2023-12-13 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
EP4313987A2 (en) 2021-04-01 2024-02-07 KRKA, d.d., Novo mesto Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4333847A1 (en) 2021-05-05 2024-03-13 Novartis AG Compounds and compositions for the treatment of mpnst
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023009438A1 (en) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
WO2023008885A1 (ko) * 2021-07-27 2023-02-02 보로노이바이오 주식회사 피롤로피리미딘 유도체 화합물 및 이의 용도
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
CN114456180B (zh) * 2022-02-18 2023-07-25 贵州大学 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
AU2023250538A1 (en) * 2022-04-08 2024-10-31 Biolexis Therapeutics, Inc. Cdk9 inhibitors
EP4504708A1 (en) * 2022-04-08 2025-02-12 Biolexis Therapeutics, Inc. Cdk9 inhibitors
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024086361A1 (en) * 2022-10-21 2024-04-25 Novartis Ag Molecular glue degrader compounds and uses thereof
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024231275A1 (en) 2023-05-05 2024-11-14 Astrazeneca Ab Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
WO2024235844A1 (en) 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
CN117069663B (zh) * 2023-08-31 2023-12-26 四川维亚本苑生物科技有限公司 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
MXPA04008592A (es) 2002-03-07 2004-12-06 Hoffmann La Roche Inhibidores de piridina biciclica y pirimidina p38 cinasa.
CA2497440C (en) 2002-09-04 2011-03-22 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
DE602004021558D1 (de) * 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
EA200600372A1 (ru) 2003-09-05 2006-08-25 Ньюроджин Корпорейшн Конденсированные с гетероарилом пиридины, пиразины и пиримидины в качестве лигандов рецептора кортикотропин-рилизинг-фактора (crf 1)
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
WO2005080393A1 (en) 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
CN1926140A (zh) 2004-03-05 2007-03-07 大正制药株式会社 吡咯并嘧啶衍生物
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
US20080167309A1 (en) 2004-07-22 2008-07-10 Astex Therapeutics, Ltd. Pharmaceutical Compounds
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
ES2508766T3 (es) 2004-10-29 2014-10-16 Janssen R&D Ireland Derivados de pirimidina bicíclicos que inhiben el VIH
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
WO2007030438A2 (en) 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007075783A2 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
BRPI0709007A2 (pt) 2006-03-09 2011-06-21 Pharmacopeia Inc inibidores de 8-heteroarilpurina mnk2 para tratamento de distúrbios metabólicos
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
AU2008343932B2 (en) * 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
KR20130066703A (ko) * 2008-02-06 2013-06-20 노파르티스 아게 피롤로［２,３­ｄ］피리미딘 및 티로신 키나제 억제제로서 그의 용도
DK2331547T3 (da) 2008-08-22 2014-11-03 Novartis Ag Pyrrolopyrimidinforbindelser som CDK-inhibitorer
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
ES2689177T3 (es) 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer

Also Published As

Publication number Publication date
JO2924B1 (en) 2015-09-15
CA2734802C (en) 2016-05-31
NI201100042A (es) 2011-08-09
US20100105653A1 (en) 2010-04-29
FR17C1059I2 (fr) 2019-01-11
CN102186856B (zh) 2014-09-24
DK2331547T3 (da) 2014-11-03
LTPA2017039I1 (lt) 2017-12-11
NO2017059I1 (no) 2017-11-13
US8685980B2 (en) 2014-04-01
TW201014858A (en) 2010-04-16
US20130184285A1 (en) 2013-07-18
US20180155351A1 (en) 2018-06-07
CU20110040A7 (es) 2011-12-28
BRPI0917791B1 (pt) 2022-03-22
NO2017059I2 (no) 2017-11-13
AR111763A2 (es) 2019-08-14
CU24062B1 (es) 2014-12-26
NL300909I2 (nl) 2017-12-19
JP5560496B2 (ja) 2014-07-30
MA32555B1 (fr) 2011-08-01
LUC00048I2 (es) 2018-01-10
CR20110101A (es) 2011-06-09
US9416136B2 (en) 2016-08-16
US20240043428A1 (en) 2024-02-08
BRPI0917791A2 (pt) 2019-08-13
CO6341561A2 (es) 2011-11-21
HN2011000542A (es) 2013-10-17
ME01282B (me) 2013-06-20
EP2716643A1 (en) 2014-04-09
US20140135312A1 (en) 2014-05-15
EA201100355A8 (ru) 2013-09-30
SI2331547T1 (sl) 2014-11-28
US20110152244A1 (en) 2011-06-23
CA2734802A1 (en) 2010-02-25
PE20110419A1 (es) 2011-07-13
HK1156625A1 (en) 2012-06-15
US20170183352A1 (en) 2017-06-29
ES2522346T3 (es) 2014-11-14
ZA201100994B (en) 2011-12-28
CY1115703T1 (el) 2017-01-25
WO2010020675A1 (en) 2010-02-25
ECSP11010843A (es) 2011-05-31
DOP2011000057A (es) 2015-11-15
LUC00048I1 (es) 2017-11-15
HRP20141018T1 (hr) 2015-02-13
KR20130140222A (ko) 2013-12-23
CN103788100A (zh) 2014-05-14
MY150560A (en) 2014-01-30
US8415355B2 (en) 2013-04-09
TN2011000062A1 (en) 2012-09-05
NZ591176A (en) 2012-11-30
AU2009284098A1 (en) 2010-02-25
TWI468409B (zh) 2015-01-11
NL300909I1 (es) 2017-11-10
US20210253578A1 (en) 2021-08-19
PL2331547T3 (pl) 2015-01-30
PT2331547E (pt) 2014-10-29
LTC2331547I2 (lt) 2018-09-10
CN102186856A (zh) 2011-09-14
US8962630B2 (en) 2015-02-24
JP5882371B2 (ja) 2016-03-09
EA201100355A1 (ru) 2011-10-31
CA2734802E (en) 2010-02-25
CL2011000306A1 (es) 2011-06-24
CY2017042I1 (el) 2018-04-04
UY38935A (es) 2020-12-31
SMT201500017B (it) 2015-03-05
JP2014129361A (ja) 2014-07-10
FR17C1059I1 (es) 2018-02-16
CY2017042I2 (el) 2018-04-04
EP2331547B1 (en) 2014-07-30
EA019094B1 (ru) 2014-01-30
KR101353857B1 (ko) 2014-01-21
KR20110052713A (ko) 2011-05-18
IL211164A (en) 2016-09-29
HUS1700051I1 (hu) 2017-12-28
IL211164A0 (en) 2011-04-28
EP2331547A1 (en) 2011-06-15
UY32067A (es) 2010-03-26
UA103628C2 (en) 2013-11-11
GEP20135785B (en) 2013-03-11
JP2012500785A (ja) 2012-01-12
RS53574B1 (en) 2015-02-27
AU2009284098B2 (en) 2012-03-29
MX2011001879A (es) 2011-03-29

Similar Documents

Publication Publication Date Title
AR073116A1 (es) Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes.
AR066781A1 (es) Compuestos de imidazopirimidina inhibidores de cinasa
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR088352A1 (es) Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CO6410301A2 (es) 1 aril -3- aminoalcoxi-pirazoles como ligandos sigma para potenciar ell efecto analgesico de los opioides y atenuar la dependencia de ellos
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
AR035716A1 (es) Compuestos agonistas del receptor beta3-adrenergico, uso de los mismos en la fabricacion de medicamentos y composiciones farmaceuticas conteniendo los mismos
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
AR050932A1 (es) Amidas biciclicas como inhibidores de cinasa
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
AR110706A1 (es) Inhibidores de poli-adp ribosa polimerasa (parp)
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
CO5700774A2 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
HRP20090235B1 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
AR087184A1 (es) Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
AR045510A1 (es) Derivados de 1,3 diazoles
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5650164A2 (es) Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FC Refusal